75 patents
Utility
Combinations of mRNAs encoding immune modulating polypeptides and uses thereof
7 Mar 23
The disclosure relates to compositions and methods for the preparation, manufacture and therapeutic use of combinations of immunomodulatory polynucleotides (e.g., mRNAs) encoding an immune response primer polypeptide (e.g., an interleukin 23 (IL-23) polypeptide or an interleukin 36γ (IL-36-gamma) polypeptide), and an immune response co-stimulatory signal polypeptide (e.g., an OX40L polypeptide).
Joshua Frederick, Ailin Bai, Vladimir Presnyak, Stephen Hoge, Kerry Benenato, Iain McFadyen, Ellalahewage Sathyajith Kumarasinghe, Susannah Hewitt
Filed: 7 Sep 22
Utility
Branched tail lipid compounds and compositions for intracellular delivery of therapeutic agents
7 Mar 23
The disclosure features novel lipids and compositions involving the same.
Kerry E. Benenato, Mark Cornebise, Edward Hennessy, Ellalahewage S. Kumarasinghe
Filed: 19 May 21
Utility
Methods for therapeutic administration of messenger ribonucleic acid drugs
28 Feb 23
The disclosure features methods of reducing or inhibiting an anti-drug antibody response in a subject, as well as methods of reducing or inhibiting unwanted immune cell activation in a subject to be treated with a messenger RNA (mRNA), comprising administering to the subject a mRNA, e.g., a chemically modified messenger RNA (mmRNA), encoding a polypeptide of interest, wherein the mRNA comprises at least one microRNA (miR) binding site for a miR expressed in immune cells, such as miR-126 binding site and/or miR-142 binding site, such that an anti-drug antibody response to the polypeptide or interest, or unwanted immune cell activation (e.g., B cell activation, cytokine secretion), is reduced or inhibited in the subject.
Stephen Hoge, Tirtha Chakraborty, Gilles Besin, Ruchi Jain
Filed: 29 Sep 20
Utility
Stabilized formulations of lipid nanoparticles
21 Feb 23
The disclosure features a lipid nanoparticle (LNP) formulation comprising a plurality of LNPs and a stabilizing agent that mitigates the degradation of the LNPs or a subpopulation thereof.
Mark Brader
Filed: 8 Nov 17
Utility
Broad spectrum influenza virus vaccine
14 Feb 23
The disclosure relates to broad spectrum influenza virus ribonucleic acid (RNA) vaccines, as well as methods of using the vaccines and compositions comprising the vaccine.
Giuseppe Ciaramella, Eric Yi-Chun Huang, Kerim Babaoglu, Jessica Anne Flynn, Lan Zhang, David Nickle
Filed: 15 Mar 18
Utility
Polynucleotides encoding interleukin-12 (IL12) and uses thereof
7 Feb 23
The present disclosure relates to polynucleotides comprising an open reading frame of linked nucleosides encoding human interleukin-12 (IL12), functional fragments thereof, and fusion proteins comprising IL12.
Joshua Frederick, Susannah Hewitt, Ailin Bai, Stephen Hoge, Vladimir Presnyak, Iain James McFadyen, Kerry Benenato, Ellalahewage Sathyajith Kumarasinghe
Filed: 15 Apr 22
Utility
Methods for preparing particles and related compositions
31 Jan 23
Methods for preparing particles and related compositions are provided.
Michael H. Smith
Filed: 17 Aug 16
Utility
Modified polynucleotides for the production of cytoplasmic and cytoskeletal proteins
31 Jan 23
The invention relates to compositions including polynucleotides encoding polypeptides which have been chemically modified by replacing the uridines with 1-methyl-pseudouridine to improve one or more of the stability and/or clearance in tissues, receptor uptake and/or kinetics, cellular access by the compositions, engagement with translational machinery, mRNA half-life, translation efficiency, immune evasion, protein production capacity, secretion efficiency, accessibility to circulation, protein half-life and/or modulation of a cell's status, function, and/or activity.
Antonin De Fougerolles, Justin Guild
Filed: 20 Sep 19
Utility
Human cytomegalovirus vaccine
3 Jan 23
The disclosure relates to HCMV ribonucleic acid (RNA) vaccines, as well as methods of using the vaccines and compositions comprising the vaccines.
Giuseppe Ciaramella, Shinu John
Filed: 10 Dec 21
Utility
Lipid nanoparticle compositions and methods of formulating the same
13 Dec 22
Provided herein are compositions and methods of reducing adduct formation.
Meredith Packer, Dipendra Gyawali, Serenus Hua, Gabor Butora, Gregory John Mercer
Filed: 22 Oct 21
Utility
Polynucleotides encoding methylmalonyl-CoA mutase
22 Nov 22
The disclosure relates to polynucleotides comprising an open reading frame of linked nucleosides encoding human methylmalonyl-CoA mutase precursor, human methylmalonyl-CoA mutase (MCM) mature form, or functional fragments thereof.
Paolo Martini, Vladimir Presnyak, Kerry Benenato, Stephen Hoge, Iain McFadyen, Ellalahewage Sathyajith Kumarasinghe
Filed: 18 Jul 19
Utility
Zoonotic disease RNA vaccines
15 Nov 22
Provide herein are Lassa virus, Nipah virus, and betacoronavirus ribonucleic acid vaccines as well as methods of using the vaccines and compositions comprising the vaccines.
Giuseppe Ciaramella, Sunny Himansu, Vladimir Presnyak, Kerry Benenato, Ellalahewage Sathyajith Kumarasinghe
Filed: 22 Jan 21
Utility
Human cytomegalovirus RNA vaccines
1 Nov 22
The disclosure describes HCMV ribonucleic acid (RNA) vaccines, as well as methods of using the vaccines and compositions comprising the vaccines.
Giuseppe Ciaramella, Shinu John, Kambiz Mousavi
Filed: 27 Mar 20
Utility
RNA polymerase variants for co-transcriptional capping
1 Nov 22
The present disclosure provides RNA polymerase variants for high efficiency transcription.
Athanasios Dousis, Kanchana Ravichandran, Amy E. Rabideau, Margaret Franklin, Kevin Smith, Michelle Lynn Hall
Filed: 20 May 21
Utility
Modified messenger RNA comprising functional RNA elements
1 Nov 22
The present disclosure provides messenger RNAs (mRNAs) having chemical and/or structural modifications, including RNA elements and/or modified nucleotides, which provide a desired translational regulatory activity to the mRNA.
Melissa J. Moore, Caroline Köhrer, Ruchi Jain, Vladimir Presnyak
Filed: 18 May 18
Utility
Respiratory syncytial virus vaccine
11 Oct 22
The disclosure describes respiratory syncytial virus (RSV) ribonucleic acid (RNA) vaccines, as well as methods of using the vaccines and compositions comprising the vaccines.
Giuseppe Ciaramella, Kapil Bahl, Amy Espeseth, Dai Wang, Andrew J. Bett
Filed: 15 Mar 18
Utility
Polynucleotides containing a morpholino linker
6 Sep 22
The disclosure provides polynucleotides encoding a polypeptide including a morpholino linker.
Gabor Butora, Andrew W. Fraley, Edward John Miracco, Jennifer Nelson, Amy Rhoden Smith, Matthew Stanton
Filed: 19 Sep 16
Utility
Polynucleotides encoding tethered interleukin-12 (IL12) polypeptides and uses thereof
23 Aug 22
The present disclosure relates to polynucleotides encoding tethered interleukin-12 (IL-12) polypeptides comprising an IL-12 polypeptide and a membrane domain.
Ankita Mishra, Joshua Frederick, Sushma Gurumurthy
Filed: 18 May 18
Utility
Human cytomegalovirus vaccine
9 Aug 22
Aspects of the disclosure relate to methods for producing an antigen-specific immune response to human cytomegalovirus (hCMV) in a subject by administering mRNA vaccines.
Jack F. Kramarczyk, Kimberly Hassett, Shinu John, Phil White, Andrea Carfi
Filed: 25 Aug 21
Utility
Methods of using OX40 ligand encoding polynucleotides
2 Aug 22
The disclosure relates to compositions and methods for the preparation, manufacture and therapeutic use of polynucleotide molecules comprising an mRNA encoding an OX40L polypeptide.
Joshua P. Frederick, Ailin Bai
Filed: 16 Mar 21